ACCLAIM Study: Microwave Ablation for Colorectal Liver Metastases

This study, called ACCLAIM, is looking at how well microwave ablation (MWA) works for treating colorectal liver metastases (cancer that has spread from the colon or rectum to the liver). MWA uses heat to destroy cancer cells. Researchers want to see if MWA can prevent the cancer from growing back in the treated area for at least two years. You might be able to join if you are at least 18 years old, have been diagnosed with colorectal cancer that has spread to your liver, and have up to three liver tumors, each no larger than 2.5 centimeters. The study aims to enroll about 275 people.

Study design
This is a multi-center study that plans to enroll about 275 participants. It is a standard of care study, meaning the treatment is already a recognized option.
What's involved
You would undergo microwave ablation, and your tumor margins will be assessed immediately after and again 4-8 weeks later. Imaging will be performed at 24 months to check for local tumor progression.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for at least 24 months to assess local tumor progression.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05265169

Ablation With Confirmation of Colorectal Liver Metastases (ACCLAIM)

Recruiting
NAAges 18+InterventionalTreatment
Society of Interventional Oncology
~275 participants
Updated 2024-01-17 on ClinicalTrials.gov
What's tested:Microwave ablation

At a glance

Recruiting sites
7 of 7 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Local tumor progression free survival at 24 months
Measured over 24 Months
Colorectal Liver Metastases
7 sites across 7 states
Florida1
Minnesota1
New York1
Texas1
Wisconsin1
Greece1
Netherlands1
  • Constantinos Sofocleous, MD, PhD, FSIR, FCIRSE · PRINCIPAL_INVESTIGATOR · Memorial Sloan Kettering Cancer Center

Opens a ready-to-send draft in your own email app — review before sending.

  • Local tumor progression free survival at 24 months24 Months

    See Above